Drug-drug in­ter­ac­tions: FDA is­sues guid­ance on clin­i­cal, in vit­ro stud­ies

The FDA on Thurs­day fi­nal­ized two guid­ances pro­vid­ing rec­om­men­da­tions to drug­mak­ers on eval­u­at­ing po­ten­tial drug-drug in­ter­ac­tions (DDIs) for new drugs through clin­i­cal and in vit­ro test­ing.

“To­geth­er, the two fi­nal guid­ances de­scribe a sys­tem­at­ic risk-based ap­proach to eval­u­a­tion and com­mu­ni­ca­tion of DDIs,” the FDA writes.

The two guid­ances fi­nal­ize draft ver­sions re­leased in 2017 and have been re­vised to clar­i­fy their scope, pro­vide ad­di­tion­al con­sid­er­a­tions for con­duct­ing prospec­tive stud­ies and to ex­plain “when DDI stud­ies are need­ed for drugs iden­ti­fied as trans­porter sub­strates from in vit­ro stud­ies.” Both guid­ances have been re­named from their draft ver­sions to re­flect an em­pha­sis on in­ves­ti­gat­ing the cy­tochrome P450 (CYP) en­zyme and trans­porter-me­di­at­ed drug in­ter­ac­tions.

The FDA ex­plains that DDIs are a crit­i­cal fac­tor in a drug’s over­all ben­e­fit-risk pro­file and stress­es that clin­i­cal­ly rel­e­vant DDIs should be iden­ti­fied dur­ing drug de­vel­op­ment, known at the time of ap­proval, in­clud­ed in la­bel­ing and mon­i­tored on an on­go­ing ba­sis.

“The con­comi­tant use of more than one med­ica­tion in a pa­tient is com­mon. Unan­tic­i­pat­ed, un­rec­og­nized, or mis­man­aged DDIs are an im­por­tant cause of mor­bid­i­ty and mor­tal­i­ty as­so­ci­at­ed with pre­scrip­tion drug use and have oc­ca­sion­al­ly been the ba­sis for with­draw­al of ap­proved drugs from the mar­ket. In some in­stances, un­der­stand­ing how to safe­ly man­age a DDI can al­low ap­proval of a drug that would oth­er­wise have an un­ac­cept­able lev­el of risk,” the FDA writes.

In Vit­ro Drug In­ter­ac­tion Stud­ies

The FDA’s 43-page guid­ance on in vit­ro drug in­ter­ac­tion stud­ies dis­cuss­es ap­proach­es to eval­u­ate the DDI po­ten­tial of in­ves­ti­ga­tion­al drugs and how those stud­ies can in­form clin­i­cal DDI stud­ies down the road.

The guid­ance ex­plains that “eval­u­at­ing the DDI po­ten­tial of an in­ves­ti­ga­tion­al new drug in­volves iden­ti­fy­ing the prin­ci­pal routes of the drug’s elim­i­na­tion; es­ti­mat­ing the con­tri­bu­tion of en­zymes and trans­porters to the drug’s dis­po­si­tion; and char­ac­ter­iz­ing the ef­fect of the drug on en­zymes and trans­porters.”

The re­sults of in vit­ro DDI stud­ies and phar­ma­co­ki­net­ic (PK) da­ta “pro­vide mech­a­nis­tic in­for­ma­tion that can in­form the need for and prop­er de­sign of po­ten­tial fu­ture clin­i­cal stud­ies.”

The guid­ance goes on to dis­cuss ap­proach­es to eval­u­at­ing me­tab­o­lism-me­di­at­ed and trans­porter-me­di­at­ed drug in­ter­ac­tions, as well as ap­proach­es to eval­u­ate the DDI po­ten­tial of metabo­lites.

Clin­i­cal Drug In­ter­ac­tion Stud­ies

In the 24-page fi­nal guid­ance on clin­i­cal drug in­ter­ac­tion stud­ies, the FDA ex­plains when DDI stud­ies should be con­duct­ed and pro­vides rec­om­men­da­tions for the de­sign, con­duct and in­ter­pre­ta­tion of those stud­ies.

Specif­i­cal­ly, the guid­ance dis­cuss­es dif­fer­ent DDI study de­signs and con­sid­er­a­tions for prospec­tive DDI stud­ies, CYP-me­di­at­ed in­ter­ac­tions, trans­porter-me­di­at­ed re­ac­tions and cock­tail study ap­proach­es. The guid­ance al­so dis­cuss­es oth­er fac­tors that could im­pact drug in­ter­ac­tions, such as pa­tient ge­net­ics, smok­ing and com­plex drug in­ter­ac­tions.

Ad­di­tion­al­ly, the guid­ance pro­vides rec­om­men­da­tions on what DDI in­for­ma­tion should be in­clud­ed in la­bel­ing and refers spon­sors to four oth­er rel­e­vant la­bel­ing guid­ances.

Fed­er­al Reg­is­ter No­tice


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Grow­ing ac­cep­tance of ac­cel­er­at­ed path­ways for nov­el treat­ments: but does reg­u­la­to­ry ap­proval lead to com­mer­cial suc­cess?

By Mwango Kashoki, MD, MPH, Vice President-Technical, and Richard Macaulay, Senior Director, of Parexel Regulatory & Access

In recent years, we’ve seen a significant uptake in the use of regulatory options by companies looking to accelerate the journey of life-saving drugs to market. In 2018, 73% of the novel drugs approved by the U.S. Federal Drug Administration (FDA) were designated under one or more expedited development program categories (Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval).ᶦ

Sanofi out­lines big API plans as coro­n­avirus out­break re­port­ed­ly threat­ens short­age of 150 drugs

As the world becomes increasingly dependant on Asia for the ingredients of its medicines, Sanofi sees business to be done in Europe.

The French drugmaker said it’s creating the world’s second largest active pharmaceutical ingredients (API) manufacturer by spinning out its six current sites into a standalone company: Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France). They have mapped out €1 billion in expected sales by 2022 and 3,100 employees for the new operations headquartered in France.

UP­DAT­ED: NGM Bio takes leap for­ward in crowd­ed NASH field

South San Francisco-based NGM Bio may have underwhelmed with its interim analysis of a key cohort from a mid-stage NASH study last fall — but stellar topline data unveiled on Monday showed the compound induced significant signs of antifibrotic activity, NASH resolution and liver fat reduction, sending the company’s stock soaring.

There are an estimated 50+ companies focused on developing drugs for non-alcoholic steatohepatitis, or NASH, a common liver disease that has long flummoxed researchers. The first wave of NASH drug developers struggled with efficacy as well as safety — and companies big and small have crashed and burned.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.

Mickey Kertesz, KidsandArtOrg via YouTube

Soft­Bank's newest, $165M biotech in­vest­ment looks for in­fec­tious traces in the blood

SoftBank has found its newest biotech investment.

The Japanese bank has invested $165 million into Karius, a company that uses blood tests to diagnose infectious diseases, as part of its new Vision Fund 2. The full scope of the new fund has yet to be announced, but the first and newly-beleaguered Vision Fund poured $100 billion into technology companies, including the biotechs Vir Biotechnology and Roivant and the sequencing company 10x Genomics.

Methicillin-resistant Staph aureus (Shutterstock)

FDA grants ‘break­through’ sta­tus to an­tibi­ot­ic al­ter­na­tive as Con­tra­Fect rush­es to join fight against su­per­bug

An experimental drug that promises to be the first anti-infective agent to prove superior to vancomycin — an antibiotic approved in 1958 — has notched the FDA’s “breakthrough” status.

ContraFect said the designation was based on Phase II data in which exebacase was tested against a superbug known as methicillin-resistant Staph aureus, or MRSA. In a subgroup analysis, the clinical responder rate at day 14 was 42.8% higher than that among those treated with standard of care, the company said (p=0.010).

Zhong Nanshan, CGTN via YouTube

Har­vard joins coro­n­avirus fight with $115 mil­lion and a high-pro­file Chi­nese part­ner

For two months, as the novel coronavirus swelled from a few early cases tied to a Wuhan market to a global epidemic, most of the world’s focus and dollars have flowed toward emergency initiatives: building vaccines at a record pace, plucking experimental antivirals out of freezers to see what sticks and immunizing mice for new antibodies.

Now a new and well-funded collaboration between Harvard and a top Chinese research institute will play the long game. In a 5-year, $115 million initiative backed by China Evergrande Group, researchers from the Harvard Medical School, Harvard T.H. Chan School of Public Health and Guangzhou Institute for Respiratory Health will study the virus in an effort to develop therapies against infections by the novel coronavirus, known as SARS–CoV-2, and to prevent new ones.

No­var­tis gets a boost in block­buster mul­ti­ple scle­ro­sis race with Roche

In the first step of what’s likely to be a long and uphill battle for the drugmaker, the FDA has accepted Novartis’s BLA submission for a new multiple sclerosis drug and given it priority review. The PDUFA date for the potential blockbuster drug is in June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.

Juergen Horn

An­i­mal health vet Juer­gen Horn makes new an­ti­body play for pets, rak­ing $15M in Se­ries A haul

Zoetis forked over $85 million in 2017 to acquire Nexvet Biopharma and its pipeline of monoclonal antibodies. Juergen Horn, Nexvet’s former chief product development officer, has now secured $15 million for his own biologic company for animals: Invetx.

Buoyed by emerging advances in gene therapies for humans, scientists have started looking at harnessing the technology for animals setting up companies such as Penn-partnered Scout Bio and George Church-founded Rejuvenate Bio. But akin to Nexvet, Invetx is working on leveraging the time-tested science of monoclonal antibodies to treat chronic diseases that afflict man’s best friend.

As coro­n­avirus out­break reach­es 'tip­ping point,' GSK lends ad­ju­vant tech to Chi­nese part­ner armed with pre­clin­i­cal vac­cine

As the coronavirus originating out of Wuhan spreads to South Korea, Italy and Iran, stoking already intense fears of a pandemic, GlaxoSmithKline has found another pair of trusted hands to place its adjuvant system. China’s Clover Biopharmaceuticals will add the adjuvant to its preclinical, protein-based vaccine candidate against SARS-CoV-2.

Clover, which is based in the inland city of Chengdu, boasts of a platform dubbed Trimer-Tag that produces covalently-trimerized fusion proteins. Its candidate, COVID-19 S-Trimer, resembles the viral spike (S)-protein found in the virus.